Santhera gibt die Zulassung von AGAMREE® (Vamorolon) zur Behandlung von Duchenne-Muskeldystrophie in Hongkong bekannt
December 20, 2024 01:00 ET
|
Santhera Pharmaceuticals Holding AG
Die Gesundheitsbehörde (Department of Health, DoH) von Hongkong hat AGAMREE® für die Behandlung von Duchenne-Muskeldystrophie (DMD) bei Patienten ab 4 Jahren zugelassen Vor kurzem hat China’s National...
Santhera Announces Approval in Hong Kong for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
December 20, 2024 01:00 ET
|
Santhera Pharmaceuticals Holding AG
Department of Health (DoH) of Hong Kong approved AGAMREE® for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older Follows recent approval from China’s National...
Duchenne Muscular Dystrophy Market to Expand from USD 2.2 Billion in 2023 to USD 7.4 Billion by 2034 – Analysis by Transparency Market Research, Inc.
December 13, 2024 10:08 ET
|
Transparency Market Research
Wilmington, Delaware, Transparency Market Research Inc., Dec. 13, 2024 (GLOBE NEWSWIRE) -- The global Duchenne muscular dystrophy market (デュシェンヌ型筋ジストロフィー市場) was valued at US$ 2.2 billion in 2023 and...
Santhera gibt die Zulassung von AGAMREE® (Vamorolone) zur Behandlung von Duchenne-Muskeldystrophie durch Chinas NMPA bekannt
December 11, 2024 01:00 ET
|
Santhera Pharmaceuticals Holding AG
Chinas National Medical Products Administration (NMPA) hat AGAMREE® für die Behandlung von Duchenne-Muskeldystrophie bei Patienten ab 4 Jahren zugelassenMit dieser Zulassung ist AGAMREE die erste und...
Santhera Announces Approval from China’s NMPA for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
December 11, 2024 01:00 ET
|
Santhera Pharmaceuticals Holding AG
China’s National Medical Products Administration (NMPA) approved AGAMREE® for the treatment of Duchenne muscular dystrophy in patients aged 4 years and olderThis approval makes AGAMREE the first and...
Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work
November 13, 2024 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Catalyst Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Provides Corporate Update
November 06, 2024 16:12 ET
|
Catalyst Pharmaceuticals, Inc.
Reports Q3 2024 Total Revenues of $128.7 Million, Representing a 25.3% YoY Increase Record Revenues Driven by Continued Organic Growth in its Rare Disease Franchise Robust Financial Performance...
Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping
September 24, 2024 07:30 ET
|
Wave Life Sciences USA, Inc.
Mean muscle content-adjusted dystrophin expression of 9.0% and unadjusted dystrophin of 5.5%, with high consistency across participants, in a prespecified analysis; dystrophin was comprised of two...
Wave Life Sciences Receives FDA Rare Pediatric Disease Designation for WVE-N531 for the Treatment of Duchenne Muscular Dystrophy
August 12, 2024 08:30 ET
|
Wave Life Sciences USA, Inc.
Designation highlights significant unmet needs in DMD; dystrophin data from potentially registrational FORWARD-53 trial of WVE-N531 are on track for 3Q 2024 In previous Part A trial, WVE-N531...
Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in Canada
July 24, 2024 08:05 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...